The hotly anticipated 13th World Clinical Biomarkers and CDx Summit returns as the only industry-led meeting uniting 600+ senior decision makers in the biomarker and CDx field to accelerate clinically validated and affordable co-development of drug-CDx by overcoming commercialization, reimbursement and regulatory challenges in oncology and beyond to bring personalized medicine to patients faster.
Whether you are working in Oncology, NASH, or Neuroscience, join 600+ Directors, Heads and VPs of Clinical Biomarkers, Translational Medicine, Precision Medicine and Companion Diagnostics together with drug and diagnostic developers, regulatory experts, payors and notified bodies for an exclusive opportunity of knowledge sharing and networking to propel your pipelines and make a marked difference for patient outcomes.
Whether you are working in Oncology, NASH, or Neuroscience, join 600+ Directors, Heads and VPs of Clinical Biomarkers, Translational Medicine, Precision Medicine and Companion Diagnostics together with drug and diagnostic developers, regulatory experts, payors and notified bodies for an exclusive opportunity of knowledge sharing and networking to propel your pipelines and make a marked difference for patient outcomes.
